Application of calycosin in pharmacy

A technology for the use of mullein isoflavone, which is applied in the field of medical use of mullein, can solve the problems of changing the pathological process of allergic diseases and cannot reduce recurrence and the like

Inactive Publication Date: 2016-01-13
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs can quickly stabilize blood vessel walls and cell walls, effectively antagonize H1 receptors, and control disease developme

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of calycosin in pharmacy
  • Application of calycosin in pharmacy
  • Application of calycosin in pharmacy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Methods: BALB / c mice were fed for 3 days after adaptive feeding, pre-administered for 2 days, the mice were shaved on the 0th day, and 1.5% FITC was applied to the hairless part of the abdomen on the 1st and 2nd days ( 80 μl of fluorescein isothiocyanate) solution was used for sensitization, and on the 6th day, 20 μl of 0.6% FITC solution was applied to the ears of mice (challenge), and the same volume of solvent was applied to the control group. After 24 hours of attack, measure the thickness of both ears of the mouse with a thickness gauge, and calculate the degree of ear swelling (right ear thickness-left ear thickness) and ear swelling inhibition rate=model group ear swelling-administration group ear swelling) / Model group ear swelling × 100%. After measuring the ear thickness, the left ear and the right ear were punched into ear pieces of the same size and weighed to calculate the difference in ear weight (weight of right ear - weight of left ear). After measuring...

Embodiment 2

[0046] Compared with the blank group, the level of IL-33 in the ear tissue (the ear tissue was obtained from the modeling method described in Implementation 1) in the model group was significantly increased, and the effect of calycosin (5 mg / kg) on ​​the IL-33 in the mouse ear tissue in the initial stage of sensitization produced a significant inhibitory effect. Other doses also had a certain downward trend in the production of IL-33.

[0047] Effect of calycosin on IL-33 in the initial stage of allergic disease sensitization

[0048] The effect of calycosin on IL-33 in the initial stage of allergic disease sensitization (mean±SD, n=8)

[0049]

[0050] *p<0.05, compared with the blank group; #p<0.05, compared with the model group;

[0051] Experiments have shown that calycosin can effectively treat allergic diseases by inhibiting the expression of IL-33 in vivo.

Embodiment 3

[0053] method:

[0054] a. Primary antibody (CaptureAntibody) coating: Dilute the CoatingBuffer (5×) with deionized water first, dilute the primary antibody with the diluted CoatingBuffer 250 times, 100 μl per well, then seal the plate with a sealing film, and incubate overnight at 4°C.

[0055] b. Pour off the CoatingBuffer on the board and pat dry with paper. Add ≥250 μl of washbuffer to each well, time for 1 min, and wash the plate five times.

[0056] c. The working solution (Assay Diluent) was diluted 5 times with deionized water, and 200 μl was added to each well. After the addition, affix a sealing film and incubate at room temperature for 1 hour.

[0057] d. Repeat operation b and wash the plate 5 times.

[0058] e. Sample addition: Dilute the standard product 1000 times with AssayDiluent to top, that is, 2000pg / ml, and then dilute the remaining 7 concentrations by 1 / 2. Add 100 μl of diluted standard and sample to each well, cover the plate with sealing film, and in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to application of calycosin in pharmacy, in particular to application of calycosin in treatment of anaphylactic diseases. The calycosin which is a main active ingredient for treatment of the anaphylactic diseases has no evident toxic or side effects on immune organs and other cells and is capable of effectively inhibiting generation and secretion of TSLP (thymic stromal lymphopoietin), IL-25 (interleukin-25) and IL-33 (interleukin-33) in core links of the anaphylactic diseases and expected to be a high-efficiency low-toxicity medicine for treatment of the anaphylactic diseases.

Description

1. Technical field [0001] The invention relates to the field of medicine, in particular to the medical application of calycosin. 2. Background technology [0002] Allergic disease (also known as allergic disease) refers to the body's response to certain substances (such as bacteria, pollen, food or drugs), circumstances (such as mental, emotional agitation, or exposure to sunlight), or physical conditions (such as exposure to cold). A paranormal or pathological reaction. The incidence of allergic diseases remains high in industrialized developed countries. In 2003, the incidence of asthma in many countries exceeded 10%, the incidence of allergic rhinitis ranged from 15-30%, and 10-20% of children suffered from atopic dermatitis. At present, many epidemiological investigations have confirmed that in recent years, the incidence of allergic diseases has been rising worldwide, especially the incidence of childhood asthma. According to WHO estimates, there are about 150 million...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P37/08A61P29/00A61P11/06A61P1/00A61P11/02A61P17/00
Inventor 洪敏于曦沈丹丹
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap